Bristol-Myers Squibb announced that Japan’s Ministry of Health, Labour and Welfare has approved Abecma (idecabtagene vicleucel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy, for the treatment of adult patients with relapsed or refractory (R/R) Multiple Myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome […]

The post Bristol Myers Squibb Receives Approval for Abecma, the First CAR T Therapy Approved for the Treatment of Multiple Myeloma in Japan first appeared on World Pharma Today.